The latest price target for Alto Neuroscience (NYSE:ANRO) was reported by Chardan Capital on January 5, 2026. The analyst firm set a price target for $30.00 expecting ANRO to rise to within 12 months (a possible 124.89% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Alto Neuroscience (NYSE:ANRO) was provided by Chardan Capital, and Alto Neuroscience maintained their buy rating.

There is no last upgrade for Alto Neuroscience

The last downgrade for Alto Neuroscience Inc happened on October 23, 2024 when Wedbush changed their price target from $29 to $4 for Alto Neuroscience Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alto Neuroscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alto Neuroscience was filed on January 5, 2026 so you should expect the next rating to be made available sometime around January 5, 2027.

While ratings are subjective and will change, the latest Alto Neuroscience (ANRO) rating was a maintained with a price target of $15.00 to $30.00. The current price Alto Neuroscience (ANRO) is trading at is $13.34, which is out of the analyst’s predicted range.